Biotricity Inc. (OTCQB: BTCY) announced its financial results for the fourth quarter and fiscal year ended March 31, 2025. Total revenue for FY2025 increased by 14.3% year-over-year to $13.79 million, building on a 25% increase in FY2024.
The company achieved a gross profit percentage of 76.6% for FY2025, a substantial improvement from 69.3% in FY2024. Total operating expenses for FY2025 decreased by $4.22 million year-over-year to $13.01 million.
The net loss attributable to common stockholders improved to $11.94 million in FY2025 from $14.93 million in the prior year. Biotricity also noted its progress towards EBITDA breakeven and long-term profitability, driven by workflow automation and AI.
As of March 31, 2025, the company had $365,145 in cash and an accumulated deficit of $138.97 million. Biotricity anticipates needing an additional $10 million in capital to fund planned operations and broader U.S. market commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.